MIMEDX to Acquire Sanara MedTech
MIMEDX announced a definitive agreement to acquire Sanara MedTech for approximately $350 million in enterprise value, or $35.00 per share, in a cash and stock transaction. The transaction is expected to be immediately accretive to revenue growth and adjusted EBITDA margins, targeting over $400 million in combined 2027 revenue with more than $20 million in anticipated run-rate cost synergies.
Key figures
- Deal Value Usd
- 350000000
- Cash component
- $33.00
- Premium to vwap
- 46%
- Enterprise value
- $350 million
- Term loan financing
- $300 million
- Offer price per share
- $35.00
- Stock component ratio
- 0.4735 shares
- Synergies annual run rate
- $20 million
- Pro forma 2027 revenue guidance
- >$400 million
- Pro forma 2027 ebitda margin guidance
- >20%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.